1 1

ARA-290

ARA-290

Base Peptides are intended for licensed medical professionals and experienced researchers. Reconstitution required. Dosing and use instructions are not provided.

$78.00
$78.00
Sale Sold out
Shipping calculated at checkout.

ARA 290 (Cibinetide) — 11-Amino-Acid Erythropoietin-Derived Tissue-Repair Peptide

ARA 290 is a synthetic 11-amino-acid peptide derived from the “helix B surface” region of Erythropoietin (EPO). It is engineered to activate the so-called “innate repair receptor” (IRR) complex (EPOR/β-common subunit) which triggers anti-inflammatory, cytoprotective and repair pathways — **without** stimulating red-blood-cell production. [oai_citation:0‡PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC4365069/?utm_source=chatgpt.com)

Identifiers
  • Synonym: Cibinetide (also known as HBSP = Helix B Surface Peptide) [oai_citation:1‡MDPI](https://www.mdpi.com/2077-0383/9/7/2225?utm_source=chatgpt.com)
  • CAS No: 1208243-50-8 [oai_citation:2‡Wikipedia](https://en.wikipedia.org/wiki/Cibinetide?utm_source=chatgpt.com)
  • Sequence (approx): pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser (11 aa) [oai_citation:3‡Wikipedia](https://en.wikipedia.org/wiki/Cibinetide?utm_source=chatgpt.com)
  • MW (≈): ~1,257 Da [oai_citation:4‡PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC4365069/?utm_source=chatgpt.com)
How It Works (Plain English)
  • Rather than act like EPO on red-blood-cells, ARA 290 selectively activates the **IRR** on tissue-repair/immune cells. [oai_citation:5‡PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC3928087/?utm_source=chatgpt.com)
  • This triggers signals that reduce inflammation, protect cells from damage (anti-apoptosis), support nerve-repair and endothelial function. [oai_citation:6‡Frontiers](https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.1096887/full?utm_source=chatgpt.com)
  • Because it bypasses the erythropoietic effects of EPO, it is explored in research for neuropathy, metabolic dysfunction, ischemia-injury and repair models. [oai_citation:7‡PubMed](https://pubmed.ncbi.nlm.nih.gov/25387363/?utm_source=chatgpt.com)
Why Researchers Use It
  • To explore **nerve-repair** and **small-fiber neuropathy** in preclinical and human models. [oai_citation:8‡PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC3563705/?utm_source=chatgpt.com)
  • To study **metabolic/inflammation cross-talk** (diabetes, lipids, tissue injury) via IRR activation. [oai_citation:9‡PubMed](https://pubmed.ncbi.nlm.nih.gov/25387363/?utm_source=chatgpt.com)
  • To model **tissue protection and repair-enhancement** (ischemia, aging, vascular injury) in animal systems. [oai_citation:10‡Frontiers](https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.1096887/full?utm_source=chatgpt.com)

Key Studies — What Was Tested, What Changed, Why It Matters

Neuropathy Pilot Trial in Sarcoidosis Patients
  • What was tested: Patients with Sarcoidosis-associated small-fiber neuropathy (SFN) treated with ARA 290 (2 mg, IV, three times weekly for 4 weeks) vs placebo. [oai_citation:11‡PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC3563705/?utm_source=chatgpt.com)
  • What changed: Significant improvement in SFNSL (Small Fibre Neuropathy Screening List) score and physical functioning (SF-36), no major safety issues. [oai_citation:12‡PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC3563705/?utm_source=chatgpt.com)
  • Why it matters: Demonstrates translational potential for peptide-mediated neuro-repair and anti-inflammation in human nervous-system injury.
Type 2 Diabetes & Neuropathy Study
  • What was tested: Adults with type 2 diabetes and neuropathic symptoms given ARA 290 (4 mg SC daily for 28 days) then followed 28 days more. [oai_citation:13‡PubMed](https://pubmed.ncbi.nlm.nih.gov/25387363/?utm_source=chatgpt.com)
  • What changed: Improvements in HbA1c, HDL/triglyceride profiles, neuropathic-symptom questionnaires and corneal nerve-fiber density vs placebo. [oai_citation:14‡PubMed](https://pubmed.ncbi.nlm.nih.gov/25387363/?utm_source=chatgpt.com)
  • Why it matters: Supports the idea that IRR-activating peptides can impact metabolic & nerve outcomes simultaneously.
Aging & Cardiac Repair Animal Study
  • What was tested: Older mice treated with ARA 290 to assess cardiac structure/function, inflammation and frailty. [oai_citation:15‡Frontiers](https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.1096887/full?utm_source=chatgpt.com)
  • What changed: Reduced age-associated blood pressure increases, preserved left-ventricular ejection fraction, lower systemic inflammatory markers. [oai_citation:16‡Frontiers](https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.1096887/full?utm_source=chatgpt.com)
  • Why it matters: Expands potential from neuropathy to systemic repair/anti-inflammation in aging and cardiovascular research.

Potential Research Applications

Nerve-Repair & Neuropathy

  • Small-fiber neuropathy (SFN), diabetic neuropathy models
  • Corneal nerve-fiber density, intra-epidermal nerve-fibre assays, pain behavior

Metabolism & Inflammation

  • HbA1c, lipid profiles, insulin-resistance models
  • Inflammatory cytokines (TNF-α, IL-1β), microglia/astrocyte activation

Tissue Protection / Aging / Ischemia

  • Ischemia-reperfusion, vascular injury, aging models, organ function (heart, kidney)
  • Cell survival endpoints (apoptosis, caspases), barrier/endothelial integrity

Synergistic Peptides (for Study Design)

GHK-Cu

  • Why pair: ECM/tissue-repair gene programs, complements ARA 290’s anti-inflammation & repair axis.
  • Angle: Gene-expression arrays (NGF/BDNF, ECM) + nerve-fiber density metrics.

TB-500 (Thymosin-β4 fragment)

  • Why pair: Cytoskeletal/angiogenic repair focus; useful in models of vascular/nerve repair alongside IRR activation.
  • Angle: Endothelial sprouting + nerve regeneration assays.

Tα1 (Thymosin-α1)

  • Why pair: Immune-modulation/anti-inflammation; complements ARA 290’s anti-inflammatory repair focus.
  • Angle: Cytokine panels + histologic nerve/vascular repair endpoints.

Design Notes

  • Clearly define vehicle, salt/form, dosing schedule (daily vs alternate day) in multi-week models.
  • Document baseline nerve metrics (e.g., IENF, CNFD) and blind assessment where possible.

Known Concerns (Context)

  • Clinical evidence, but limited long-term data:
  • Short half-life & delivery:
  • Research use only:

Specifications & Handling

  • Form: Lyophilized peptide powder (lot-coded) — verify independent COA.
  • Purity: Typically ≥ 99 % (HPLC/MS verified) in research-grade peptides.
  • Storage: ≤ −20 °C; protect from light/moisture; minimize freeze–thaw cycles.
  • In solution:
  • Packaging: Tamper-evident; labeled “research use only.”

Regulatory & Use Notice

Sold for laboratory research use only. Not for human consumption, medical, or veterinary use. No human-use instructions are provided. Buyer is responsible for safe handling and regulatory compliance.

ARA 290 Peptide Research | Cibinetide | Innate Repair Receptor, Anti-Inflammation & Nerve-Repair Studies

Keywords: ARA-290 peptide, Cibinetide, HBSP, helix B surface peptide, innate repair receptor, small fiber neuropathy, diabetic neuropathy, tissue repair peptide, Base Peptides.

View full details

Instructions are NOT provided before or after purchase.

Peptide molecules are unfinished and require reconstitution from a skilled and licensed professional to activate the compound into liquid form. Instructions are not provided for reconstitution, dosing, or adminstration. All products are strictly intended for research purposes and laboratory experimentation. Handling should be by skilled licensed and credentialed professionals only. Non experimental use is strictly prohibited.
Keep Shopping